Read by QxMD icon Read

Androgen breast

Giuseppe Loverro, Leonardo Resta, Miriam Dellino, Di Naro Edoardo, Maria Arcangela Cascarano, Matteo Loverro, Salvatore Andrea Mastrolia
OBJECTIVE: Female-to-male transition remains a specific clinical indication for long-term testosterone administration. There is a limited number of studies dealing with the effect of androgen treatment on their female receptive targets (mainly breast and uterus) and the knowledge in this field is scarce and, sometimes, contradictory. MATERIALS AND METHODS: We performed a prospective study including 12 patients aged between 20 years and 32 years, with a diagnosis of gender dysphoria, treated with parenteral testosterone administration before sexual reassignment surgery...
October 2016: Taiwanese Journal of Obstetrics & Gynecology
Maria Magdalena Montt-Guevara, Jorge Eduardo Shortrede, Maria Silvia Giretti, Andrea Giannini, Paolo Mannella, Eleonora Russo, Alessandro David Genazzani, Tommaso Simoncini
The relationship between androgens and breast cancer is controversial. Androgens have complex effects on breast cancer progression and metastasis. Moreover, androgen receptor (AR) is expressed in approximately 70 to 90% of invasive breast carcinomas, which has prognostic relevance in basal-like cancers and in triple-negative breast cancers. Recent studies have associated the actin-binding proteins of the ezrin-radixin-moesin (ERM) family with metastasis in endocrine-sensitive cancers. We studied on T47D breast cancer cells whether androgens with different characteristics, such as testosterone (T), dihydrotestosterone (DHT), and dehydroepiandrosterone (DHEA) may regulate breast cancer cell motility and invasion through the control of actin remodeling...
2016: Frontiers in Endocrinology
Elgene Lim, Gerard Tarulli, Neil Portman, Theresa Hickey, Wayne D Tilley, Carlo Palmieri
The estrogen receptor-α (herein called ER) is a nuclear sex steroid receptor (SSR) that is expressed in approximately 75% of breast cancers. Therapies that modulate ER action have substantially improved the survival of patients with ER-positive breast cancer, but resistance to treatment still remains a major clinical problem. Treating resistant breast cancer requires co-targeting of ER and alternate signalling pathways that contribute to resistance to improve the efficacy and benefit of currently available treatments...
October 11, 2016: Endocrine-related Cancer
Jane Date C Hon, Baljit Singh, Aysegul Sahin, Gang Du, Jinhua Wang, Vincent Y Wang, Fang-Ming Deng, David Y Zhang, Marie E Monaco, Peng Lee
Treatment protocols for breast cancer depend predominantly on receptor status with respect to estrogen (estrogen receptor alpha), progesterone (progesterone receptor) and human epidermal growth factor [human epidermal growth factor receptor 2 (HER2)]. The presence of one or more of these receptors suggests that a treatment targeting these pathways might be effective, while the absence of, or in the case of HER2, lack of overexpression of, all of these receptors, termed triple negative breast cancer (TNBC), indicates a need for the more toxic chemotherapy...
2016: American Journal of Cancer Research
Sung Gwe Ahn, Seung Jun Kim, Cheungyeul Kim, Joon Jeong
Tumor heterogeneity of triple-negative breast cancer (TNBC) has been the main barrier in conquering breast cancer. To dissect the molecular diversity of TNBC and discover therapeutic targets for TNBC, the molecular classification of TNBC is a prioritized issue in research area. Accordingly, recent studies have been successful in classifying TNBC into several distinct subtypes with specific biologic pathways. Despite the different methodologies used and varied number of final subtypes, these studies identically suggested that TNBC consists of four major subtypes: basal-like, mesenchymal, luminal androgen receptor, and immune-enriched...
September 2016: Journal of Breast Cancer
R Mimoto, Y Imawari, S Hirooka, H Takeyama, K Yoshida
Whereas accumulating studies have supported the cancer stem cell theory, a specific therapy targeting a cancer stem cell subpopulation has not been established. Here, we show that dual-specificity tyrosine phosphorylation-kinase 2 (DYRK2) is a novel negative regulator for formation of breast cancer stem cells. Downregulation of DYRK2 promotes cancer stem-like traits in vitro, tumourigenesis in vivo and the proportion of the cancer stem cell population in human breast cancer tissues. We found that Krupple-like factor 4 (KLF4) serves as a key mediator of DYRK2's control over the cancer stem phenotype...
October 10, 2016: Oncogene
Roberta Baravalle, Giovanna Di Nardo, Andrea Bandino, Ines Barone, Stefania Catalano, Sebastiano Andò, Gianfranco Gilardi
The cytochrome P450 aromatase is involved in the last step of sex hormones biosynthesis by converting androgens into estrogens. The human enzyme is highly polymorphic and literature data correlate aromatase single nucleotide polymorphisms to the onset of pathologies such as breast cancer and neurodegenerative diseases. The aims of this study were i) to study the influence of the mutations R264C and R264H on the structure-function of the enzyme also upon phosphorylation by selected kinases and ii) to compare the activity of the variants to that of aromatase wild type in two different cell lines...
October 1, 2016: Journal of Steroid Biochemistry and Molecular Biology
Oliver Politz, Franziska Siegel, Lars Bärfacker, Ulf Bömer, Andrea Hägebarth, William J Scott, Martin Michels, Stuart Ince, Roland Neuhaus, Kirstin Meyer, Amaury Ernesto Fernández-Montalván, Ningshu Liu, Franz von Nussbaum, Dominik Mumberg, Karl Ziegelbauer
The PI3K-AKT-mTOR signaling cascade is activated in the majority of human cancers, and its activation also plays a key role in resistance to chemo and targeted therapeutics. In particular, in both breast and prostate cancer, increased AKT pathway activity is associated with cancer progression, treatment resistance, and poor disease outcome. Here, we evaluated the activity of a novel allosteric AKT1/2 inhibitor, BAY 1125976, in biochemical, cellular mechanistic, functional, and in vivo efficacy studies in a variety of tumor models...
October 3, 2016: International Journal of Cancer. Journal International du Cancer
Fumi Nozaki, Yukari Hirotani, Yoko Nakanishi, Hiromi Yamaguchi, Haruna Nishimaki, Hiroko Noda, Xiaoyan Tang, Hisae Yamamoto, Atsuko Suzuki, Toshimi Seki, Shinobu Masuda
p62, also called sequestosome 1 (SQSTM1), is a multifunctional signaling molecule that affects cell proliferation. Recently, we found accumulation of p62 in apocrine carcinoma of the breast, however, the biological role of p62 expression in apocrine carcinoma still remains unclear. To investigate whether p62 might contribute to tumor cell proliferation in apocrine carcinomas, we used the MDA-MB-453 (androgen receptor-positive, HER2-type) and MFM223 (androgen receptor-positive, triple-negative type) breast cancer cell lines as models of molecular apocrine carcinoma...
August 30, 2016: Acta Histochemica et Cytochemica
C Speers, S G Zhao, A Santola, M Liu, K Wilder-Romans, P G Alluri, T S Lawrence, F Feng, L J Pierce
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
M Abazeed, B Yard
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
Miho Kono, Takeo Fujii, Genevieve Ray Lyons, Lei Huo, Roland Bassett, Yun Gong, Meghan Sri Karuturi, Debu Tripathy, Naoto T Ueno
PURPOSE: The purpose of this study is to evaluate survival outcome in patients with hormone receptor (HR)-positive (+) metastatic breast cancer (MBC) who received fluoxymesterone after disease progression while receiving contemporary hormonal therapy, as well as the association between estrogen receptor (ER)/androgen receptor (AR) status and survival outcome in these patients. METHODS: We retrospectively identified 103 patients treated with fluoxymesterone for HR + MBC from 2000 to 2014 and with at least one previous hormonal therapy in a metastatic setting...
November 2016: Breast Cancer Research and Treatment
Francesca Collina, Margherita Cerrone, Valentina Peluso, Michelino De Laurentiis, Roberta Caputo, Rossella De Cecio, Giuseppina Liguori, Gerardo Botti, Monica Cantile, Maurizio Di Bonito
Developing of personalized therapies for Triple Negative Breast Cancer (TNBC) requires a more detailed knowledge of its biology and a correct stratification of molecular subtypes. Androgen Receptor (AR) is expressed in a large part of TNBCs but its prognostic role in this Breast Cancer (BC) subtype is highly debated. In this study, we analyzed AR expression in a series of 238 TNBCs and correlated its expression with clinical-pathological features, survival, and metabolic profile. We showed a consistent association between AR expression and a better prognosis of TNBC patients, while its downregulation appeared strongly associated with diabetic disease...
2016: American Journal of Translational Research
Saichon Chaiwongwatanakul, Pattamawadee Yanatatsaneejit, Sissades Tongsima, Apiwat Mutirangura, Viroj Boonyaratanakornkit
Long interspersed elements-1s (LINE-1s) are dispersed all over the human genome. There is evidence that hypomethylation of LINE-1s and levels of sex steroids regulate gene expression leading to cancer development. Here, we compared mRNA levels of genes containing an intragenic LINE-1 in breast cancer cells treated with various sex steroids from Gene Expression Omnibus (GEO), with the gene expression database using chi-square analysis ( We evaluated whether sex steroids influence expression of genes containing an intragenic LINE-1...
2016: Asian Pacific Journal of Cancer Prevention: APJCP
Hee Young Na, Ji-Young Choe, Seon Ah Shin, Ho-Kyung Choung, Sohee Oh, Jin-Haeng Chung, Mira Park, Ji Eun Kim
Despite recent progress in comprehensive genetic analysis, little is known about the molecular pathogenesis of sebaceous carcinoma. On the basis of the ontogenic proximity of sebaceous and mammary glands, we designed an intrinsic classification for sebaceous carcinoma adapted from that of breast cancer and evaluated its clinical significance. We investigated 42 cases of sebaceous carcinoma, including 32 ocular and 10 extraocular cases. Immunohistochemical analyses for estrogen receptor (ER), progesterone receptor (PR), androgen receptor (AR), HER2, Ki67, and CK5/6 and fluorescence in situ hybridization for the HER2 gene were performed...
September 14, 2016: American Journal of Surgical Pathology
Roberta Baravalle, Francesca Valetti, Gianluca Catucci, Giovanna Gambarotta, Mario Chiesa, Sara Maurelli, Elio Giamello, Ines Barone, Stefania Catalano, Sebastiano Andò, Giovanna Di Nardo, Gianfranco Gilardi
Aromatase catalyses the conversion of androgens into estrogens and is a well-known target for breast cancer therapy. As it has been suggested that its activity is affected by inhibitors of phosphodiesterase-5, this work investigates the potential interaction of sildenafil with aromatase. This is carried out both at molecular level through structural and kinetics assays applied to the purified enzyme, and at cellular level using neuronal and breast cancer cell lines. Sildenafil is found to bind to aromatase with a KD of 0...
September 8, 2016: Journal of Steroid Biochemistry and Molecular Biology
Nada El Ghorayeb, Solange Grunenwald, Serge Nolet, Vanessa Primeau, Stéphanie Côté, Christine M Maugard, André Lacroix, Louis Gaboury, Isabelle Bourdeau
BACKGROUND: Adrenocortical carcinoma (ACC) may rarely be a component of inherited cancer syndromes such as Li-Fraumeni syndrome and Beckwith-Wiedemann syndrome. ACC caused by a BRCA2 mutation has never been reported. METHODS: Nucleotide sequencing of BRCA2 in lymphocyte and tumoral DNA of a 50-year-old male who presented with an androgen-secreting ACC and a strong family history of breast, ovarian, and pancreatic cancers. RESULTS: A germline BRCA2 2 bp heterozygous deletion at nucleotide 8765 (8765delAG) leading to a frameshift mutation (p...
September 2016: Medicine (Baltimore)
Antonio Ieni, Valeria Barresi, Giuseppina Rosaria Rita Ricciardi, Barbara Adamo, Vincenzo Adamo, Giovanni Tuccari
No abstract text is available yet for this article.
2016: Breast Cancer: Targets and Therapy
Victoria D Balise, Chun-Xia Meng, Jennifer N Cornelius-Green, Christopher D Kassotis, Rana Kennedy, Susan C Nagel
This systematic review identified 45 original published research articles related to oil and gas extraction activities and human reproductive endpoints. Reproductive outcomes were categorized as [1] birth outcomes associated with maternal exposure, [2] semen quality, fertility, and birth outcomes associated with adult paternal exposure, [3] reproductive cancers, and [4] disruption of human sex steroid hormone receptors. The results indicate there is moderate evidence for an increased risk of preterm birth, miscarriage, birth defects, decreased semen quality, and prostate cancer...
September 15, 2016: Fertility and Sterility
Nicholas C D'Amato, Michael A Gordon, Beatrice Babbs, Nicole S Spoelstra, Kiel T Carson Butterfield, Kathleen C Torkko, Vernon T Phan, Valerie N Barton, Thomas J Rogers, Carol A Sartorius, Anthony Elias, Jason Gertz, Britta M Jacobsen, Jennifer K Richer
: Androgen receptor (AR) is expressed in 90% of estrogen receptor alpha positive (ER+) breast tumors, but its role in tumor growth and progression remains controversial. Use of two anti-androgens that inhibit AR nuclear localization, enzalutamide and MJC13, revealed that AR is required for maximum ER genomic binding. Here, a novel global examination of AR chromatin binding found that estradiol induced AR binding at unique sites compared to dihydrotestosterone (DHT). Estradiol-induced AR binding sites were enriched for estrogen response elements and had significant overlap with ER binding sites...
August 26, 2016: Molecular Cancer Research: MCR
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"